Developments and challenges in neoadjuvant therapy for locally advanced pancreatic cancer

doi:10.3748/wjg.v29.i35.5094

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 29, Issue 35

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3788)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-3) series.

Item

Count

PDF

WORD

HTML

2412

Tables (1-3)

260

Sum=2813

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

144

Download

260

Sum=404

Publishing Process of This Article

Item

Count

Browse

162

Download

222

Sum=384

Sep 21, 2023 (publication date) through Nov 9, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Sep 21, 2023; 29(35): 5094-5103
Published online Sep 21, 2023. doi: 10.3748/wjg.v29.i35.5094

Table 3 Monoclonal antibody-based therapies targeting non-immune cells for pancreatic ductal adenocarcinoma

Ref.	Type of study	Years of accrual	Target	mAb
NCT01521325[44]	Phase 1	2011-2013	Mesothelin	MORAb-009
Patel et al[45]	Preclinical study	2013	MUC-5AC	NPC-1C
NCT03376659[46]	Phase 1/Phase 2	2018-2023	VEGF	Bevacizumab
NCT00614653[47]	Phase 1	2008-2016	VEGF	Bevacizumab
O'Sullivan et al[48]	Preclinical study	2017	AnxA6	9E1
Smith et al[49]	Phase 1	2008-2011	DLL4	Demcizumab
NCT02722954[50]	Phase 1	2016-2017	DLL4	Demcizumab

AnxA6: Annexin A6; DLL4: Delta-like ligand 4; mAb: Monoclonal antibody; MUC: Mucin; VEGF: Vascular endothelial growth factor.

Citation: Zhou B, Zhang SR, Chen G, Chen P. Developments and challenges in neoadjuvant therapy for locally advanced pancreatic cancer. World J Gastroenterol 2023; 29(35): 5094-5103
URL: https://www.wjgnet.com/1007-9327/full/v29/i35/5094.htm
DOI: https://dx.doi.org/10.3748/wjg.v29.i35.5094